statnews.com·Mar 9, 2026
Vertex's drug has successfully reduced a key marker of IgA nephropathy by half in a Phase 3 trial, positioning the company in a competitive race with Otsuka and Vera Therapeutics to treat this kidney disease, which affects 330,000 people in the U.S. and Europe.
Vertex's recent success in reducing a key marker of IgA nephropathy in a Phase 3 trial positions its drug as a strong contender against Otsuka and Vera Therapeutics, with projected annual sales of $4 billion or more. For someone tracking healthtech and biotech investment opportunities, this could signal a significant valuation boost for Vertex, presenting a potentially lucrative investment opportunity in the biotech sector, especially in the race to treat kidney diseases.